This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SCHAUMBURG, Ill., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Ondansetron Injection, USP, an antiemetic, in two latex-free vial presentations. According to IMS, for the 12 months ending June 2012, the US market for Ondansetron Injection, USP approximated $49 million. As with all products in Sagent's portfolio, Ondansetron features the company's PreventIV Measures
SM packaging and labeling, designed to help reduce medication errors.
About Ondansetron Injection, USP
Ondansetron Injection, USP is indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and for prevention of postoperative nausea and/or vomiting.
The package insert, available at
www.sagentpharma.com , contains the indications, complete side effect profile, and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.